CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma
Open Access
- 6 March 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10, 302
Abstract
We developed a computational pipeline designed to use RNA sequencing (n = 136) and gene expression profiling (n = 250) data from neuroblastoma tumors to identify cell surface proteins predicted to be highly expressed in MYCN amplified neuroblastomas and with little or no expression in normal human tissues. We then performed ChIP-seq in the MYCN amplified cell lines KELLY, NB-1643, and NGP to identify gene promoters that are occupied by MYCN protein to define the intersection with the differentially-expressed gene list. We initially identified 116 putative immunotherapy targets with predicted transmembrane domains, with the most significant differentially-expressed of these being the calmodulin kinase-like vesicle-associated gene (CAMKV, p = 2 × 10−6). CAMKV encodes a protein that binds calmodulin in the presence of calcium, but lacks the kinase activity of other calmodulin kinase family members. We confirmed that CAMKV is selectively expressed in 7/7 MYCN amplified neuroblastoma cell lines and showed that the transcription of CAMKV is directly controlled by MYCN. From membrane fractionation and immunohistochemistry, we verified that CAMKV is membranous in MYCN amplified neuroblastoma cell lines and patient-derived xenografts. Finally, immunohistochemistry showed that CAMKV is not expressed on normal tissues outside of the central nervous system. Together, these data demonstrate that CAMKV is a differentially-expressed cell surface protein that is transcriptionally regulated by MYCN, making it a candidate for targeting with antibodies or antibody-drug conjugates that do not cross the blood brain barrier.Keywords
Funding Information
- American Association for Cancer Research
- Alex's Lemonade Stand Foundation for Childhood Cancer
- National Institutes of Health
This publication has 49 references indexed in Scilit:
- Targeting MYCN in Neuroblastoma by BET Bromodomain InhibitionCancer Discovery, 2013
- MaSC: mappability-sensitive cross-correlation for estimating mean fragment length of single-end short-read sequencing dataBioinformatics, 2013
- Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplificationProceedings of the National Academy of Sciences, 2012
- Cell‐surface Metalloprotease ADAM12 is Internalized by a Clathrin‐ and Grb2‐dependent MechanismTraffic, 2012
- AdapterRemoval: easy cleaning of next-generation sequencing readsBMC Research Notes, 2012
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for NeuroblastomaNew England Journal of Medicine, 2010
- Recent Advances in NeuroblastomaNew England Journal of Medicine, 2010
- Fast and accurate short read alignment with Burrows–Wheeler transformBioinformatics, 2009
- Model-based Analysis of ChIP-Seq (MACS)Genome Biology, 2008
- Chromatin immunoprecipitation and microarray-based analysis of protein locationNature Protocols, 2006